Summary

Hidradenitis suppurativa (HS) is a chronic, painful skin disease for which there is currently no approved treatment. Results from the Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa [PIONEER II; NCT01468233] show that patients with moderate-to-severe HS who are treated with adalimumab experience a clinically relevant reduction in objective disease activity and pain after 12 weeks, as discussed in this article.